Giulia Fiorentini

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

M. Filippi, S. Bonassi, F. Vernieri, 2022, The Journal of Headache and Pain.

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment

F. Vernieri, C. Altamura, P. Barbanti, 2022, Headache.

The first report of the Italian Migraine Registry (I-GRAINE)

B. Colombo, S. Bonassi, F. Vernieri, 2022, Neurological Sciences.

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

M. Filippi, G. Sette, D. Le Pera, 2023, The Journal of Headache and Pain.

Very-low-calorie ketogenic diet vs hypocaloric balanced diet in the prevention of high-frequency episodic migraine: the EMIKETO randomized, controlled trial

E. Moriconi, A. Feraco, V. Marzolla, 2023, Journal of Translational Medicine.

Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

F. Vernieri, C. Altamura, P. Barbanti, 2024, Journal of neurology.

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

L. Borrello, A. Doretti, G. Egeo, 2024, Neurology and therapy.

Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study

P. Barbanti, G. Egeo, C. Aurilia, 2024, Journal of neurology.